12/23
01:28 pm
mdgl
Here are the most and least likely M&A targets in biotech, according to Truist [Seeking Alpha]
Low
Report
Here are the most and least likely M&A targets in biotech, according to Truist [Seeking Alpha]
12/19
02:28 pm
mdgl
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1-Year Share Price Surge [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL): Reassessing Valuation After Strong 1-Year Share Price Surge [Yahoo! Finance]
12/19
08:02 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $900.00 price target on by analysts at UBS Group AG.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $900.00 price target on by analysts at UBS Group AG.
12/19
07:19 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
12/18
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
12/15
04:21 pm
mdgl
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
12/15
04:05 pm
mdgl
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
Low
Report
Madrigal Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference
12/11
09:10 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at B. Riley.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its "buy" rating reaffirmed by analysts at B. Riley.
12/9
08:11 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.
12/4
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
12/1
08:11 am
mdgl
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Surged Following the Strong Launch and Execution of New Drug [Yahoo! Finance]
11/21
11:27 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $568.00 to $620.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $568.00 to $620.00. They now have a "buy" rating on the stock.
11/20
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
11/20
08:07 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $600.00 to $650.00. They now have an "outperform" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Oppenheimer Holdings, Inc. from $600.00 to $650.00. They now have an "outperform" rating on the stock.
11/19
12:59 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Truist Financial Corporation from $580.00 to $640.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Truist Financial Corporation from $580.00 to $640.00. They now have a "buy" rating on the stock.
11/18
10:42 pm
mdgl
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis [Yahoo! Finance]
Low
Report
Madrigal Pharmaceuticals (MDGL) Is Up 5.7% After Positive Phase 3 Rezdiffra Results in Advanced MASH Cirrhosis [Yahoo! Finance]
11/17
08:12 am
mdgl
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences [Yahoo! Finance]
Medium
Report
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences [Yahoo! Finance]
11/17
08:00 am
mdgl
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
Medium
Report
Madrigal Pharmaceuticals Announces Participation at Three Upcoming Investor Conferences
11/13
04:04 pm
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $526.00 to $587.00. They now have a "buy" rating on the stock.
Low
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Canaccord Genuity Group Inc. from $526.00 to $587.00. They now have a "buy" rating on the stock.
11/11
11:42 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $500.00 to $568.00. They now have a "buy" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at HC Wainwright from $500.00 to $568.00. They now have a "buy" rating on the stock.
11/10
08:40 am
mdgl
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis [Yahoo! Finance]
Low
Report
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis [Yahoo! Finance]
11/10
08:00 am
mdgl
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
Low
Report
Madrigal Presents New Data Demonstrating Rezdiffra® (resmetirom) Significantly Improved Multiple Noninvasive Imaging Tests and Biomarkers in Patients with Compensated MASH Cirrhosis
11/6
04:05 pm
mdgl
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
11/5
08:10 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $527.00 price target on by analysts at JMP Securities.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) was given a new $527.00 price target on by analysts at JMP Securities.
11/5
08:07 am
mdgl
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $485.00 to $527.00. They now have a "market outperform" rating on the stock.
Medium
Report
Madrigal Pharmaceuticals (NASDAQ:MDGL) had its price target raised by analysts at Citizens Jmp from $485.00 to $527.00. They now have a "market outperform" rating on the stock.